It has been shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors have pleiotropic effects and that human serum paraoxonase (PON1) inhibits the oxidative modification of low-density lipoprotein. We investigated the 
INTRODUCTION
Human serum paraoxonase (PON1) is an esterase that hydrolyzes aromatic carboxylic acid esters, organophosphates and carbonates. It is noted that PON1 associates with high-density lipoprotein (HDL) [1] and inhibits the oxidation of low-density lipoprotein (LDL) and HDL [2, 3] . PON1 knockout mice were unable to protect against the progression of atherosclerosis by feeding on a high fat and high cholesterol diet [4] , and atherosclerotic lesion formation was decreased in PON1 transgenic mice [5] . We are included among researchers who have reported that PON1 activity is related not only to macroangiopathy, but also to microangiopathy, such as retinopathy and nephropathy in diabetic patients [6] [7] [8] . These reports indicate that PON1 has effects against oxidative disorders in vivo and also that it plays an important role in the suppression of the development and progression of atherosclerosis [9] .
A clinical trail has shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have various pleiotropic effects against atherosclerosis apart from their cholesterol-lowering action [10] . Anti-oxidation 5 has been suggested as one of the pleiotropic effects of statins [11] . Also, simvastatin has been reported to inhibit macrophage-dependent LDL oxidization [12] , and atorvastatin to inhibit copper-derived LDL oxidization [13] .
Clinical studies showed that simvastatin normalized the lower enzyme activity of PON1 in patients with familial hypercholesterolemia [14] and that the statin increased the serum concentrations and activities of PON1 in patients with hypercholesterolemia [15] . We previously reported using a reporter gene assay method showing that pitavastatin enhanced the promoter activity of the PON1 gene in HepG2 cells of a human hepatocellular carcinoma cell line and in human embryonic kidney 293 (HEK293) cells through a depletion of mevalonic acid-derived farnesyl pyrophosphate [16] . Deakin et al. reported that simvastatin increased sterol regulatory element-binding protein-2 (SREBP-2) binding to PON1 DNA, and that SREBP-2 up-regulated PON1 gene promoter activity in HepG2 cells [15] . SREBP-2 is a transcription factor that is a major regulator of cholesterol homeostasis and that is activated by cellular cholesterol depletion. It was recently demonstrated that SREBP-2 was linked to p44/42 6 mitogen-activated protein (MAP) kinase signaling cascade [17, 18] . On the other hand, statins regulate the induction of various proteins or genes through an activation of MAP kinase signaling cascades [19] [20] [21] . However, there have been no reports in related literature that MAP kinase signaling cascades are involved in PON1 protein expression or its promoter activation in human hepatocytes.
In the present study, we investigated whether pitavastatin stimulated PON1 gene promoter activity and affected its protein expression through MAP kinase signaling cascades in cultured human hepatoma Huh7 cells in vitro. We showed that pitavastatin increased PON1 gene promoter activity and PON1 protein expression and that these effects were regulated by p44/42 MAP kinase signaling cascade.
MATERIALS and METHODS

Cell culture and maintenance
Huh7 cells were cultured and maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St. Louis, MO) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Life Technologies, Rockville, MD), 100 U/ml penicillin (Life Technologies) and 20 μg/ml streptomycin (Life Technologies) in 90-mm plastic plates (Nunc, Roskilde, Denmark), and incubated at 37°C in 5% CO 2 . The cells were seeded into 90-mm tissue culture plates and routinely passaged every 3-4 days. These cells were seeded into 24-well plastic plates (Corning, Corning, NY) for luciferase assays and 6-well plastic plates (Nunc) for Western blotting.
Treatment and reagents
Pitavastatin was gifted from Kowa Ltd. (Tokyo, Japan). PD98059 and U0126 were purchased from Promega (Madison, WI), and SP600125 and SB203580 from Sigma. All of the above reagents were dissolved in dimethyl 8 sulfoxide (DMSO) (Nakarai Tesque, Kyoto, Japan) adjusted with DMEM to a final concentration of 0.1%. The medium of control wells was adjusted to 0.1% DMSO. Plasmid constructs were transfected 120 min before treatment with each reagent for luciferase assay.
Plasmid constructs and transfection
We used plasmid constructs with PON1 gene 5'-flanking regions for luciferase assay, as reported previously [22] . pGL3 luciferase reporter vectors (Promega) introduced DNA fragments of PON1 genes (-587/-6) (pGL3-PON1[587/-6]) were used in the present study. The number of DNA fragments is shown from the ATG start codon because of multi-transcription sites of the PON1 genes.
We used an expression vector of the specificity protein 1 (Sp1) for mammalian cells, as reported previously [16] . We also constructed an expression vector of SREBB-2 and a mutated form at the positions of major p44/42 MAP-kinase specific phosphorylation sites, whose Ser-432 and Ser-455 were substituted with Ala (pCL-SREBP-2 S432/455A) according to previous reports [18] . The mutated construct was made by using a mutagenesis kit 
Cell lysis and Western blotting
Huh7 cells were grown to confluence, harvested, and lysed as described previously [23] . The protein concentration was adjusted (Bio-Rad Protein Assay, Bio-Rad, Hercules, CA). Western blotting was performed as described previously [23] . Antibodies for PON1 [8] 
Preparation of nuclear extracts and electrophoretic mobility shift assay (EMSA)
Huh7 cells were grown to confluence and harvested, and the nuclear fraction was isolated and extracted as described previously [16, 23] . EMSA was performed as described previously [16, 23] . The synthetic sense and antisense strands of oligonucleotides (-187/-159) were 5'-GGTGGGGGCTGACCGCAAGCCGCGC-3' and 5'-GGCGCGGCTTGCGGTCAGCCCCCAC-3', respectively. For a supershift study, Sp1-specific polyclonal antibody (PEP2) (Santa Cruz Biotechnology, Santa Cruz, CA) was used. The dried gel was analyzed by a computerized system for radioluminography (BAS2500, Fuji Photo Film, Kanagawa, Japan) and for analyzing software (MacBAS version 2.3, Fuji Photo Film). The intensities of bands were compared by using the software. Each experiment was repeated at least three times, and representative results are shown.
Statistical analysis
Comparisons for two groups were performed using the Tukey-Kramer test.
Statistical differences among three groups or more were determined by analysis of variance (ANOVA). P values <0.05 were considered statistically significant.
RESULTS
Effects of pitavastatin on PON1 promoter activity and PON1 protein expression
We previously reported that pitavastatin enhanced the promoter activity of PON1 gene in HepG2 cells using a reporter gene assay method and that we could detect PON1 mRNA but not PON1 protein in HepG2 cells [22] . Huh7 is another human hepatoma cell line and expresses PON1 protein. Consequently, in the present study we examined the effects of pitavastatin on PON1 promoter activity and PON1 protein expression in Huh7 cells. PON1 promoter activity was significantly increased dose-dependently by pitavastatin from 5 to 50 µM (relative promoter activity; 1.0 ± 0.1 at pitavastatin 0 μM, 1.6 ± 0.1 at 5 μM, 1.6 ± 0.1 at 10 μM, 1.7 ± 0.1 at 20 μM and 1.9 ± 0.1 at 50 μM). PON1 protein expression was increased dose-dependently by pitavastatin from 0.1 to 10 µM in Huh7 cells after 24 h.
Effects of pitavastatin on MAP kinase signaling cascades
We examined the effects of pitavastatin on the activation of p44/42 MAP kinase signaling cascade, using immunoblotting in Huh7 cells through 120 min (Fig 1A) . Pitavastatin 10 µM phosphorylated p44/42 MAP kinase after 5 min, and this effect was bolstered for 60 min. Pitavastatin 0.1-20 µM dose-dependently effected on the phosphorylation of p44/42 MAP kinase in 60 min incubation ( Fig   1B) . On the other hand, 10 µM pitavastatin affected neither the phosphorylation of SAPK/JNK nor p38 MAP kinase (Fig 1C and 1D) .
Role of MAP kinase signaling cascades in pitavastatin-enhanced PON1 promoter activation
We examined which pathway in the MAP kinase signaling cascades was involved in pitavastatin-induced PON1 promoter activation in Huh7 cells. Each specific inhibitor of MAP kinase signaling cascades was added to cell cultures 2 h after plasmid transfection. PON1 promoter activity was measured at 24 h after treatment. Both 10 µM PD98059 (MAP kinase kinase I inhibitor) and 10 µM U0126 (MAP kinase kinase inhibitor) attenuated the pitavastatin-induced 15 increase in promoter activity (Fig 2A and 2B ). Neither SP600125 (SAPK/JNK inhibitor) nor SB203580 (p38 MAP kinase inhibitor) abolish the pitavastatin-induced increase in promoter activity (Fig 2C and 2D) .
Role of p44/42 MAP kinase signaling cascade in pitavastatin-enhanced
PON1 protein expression
Because the phosphorylation of p44/42 MAP kinase was related to the pitavastatin-induced activation of PON1 promoter, we studied whether the pitavastatin-induced phosphorylation of p44/42 MAP kinase was an influence on the PON1 protein expression in Huh7 cells (Fig 3) . The PON1 protein expression in Huh7 cells was significantly increased by 10 µM pitavastatin (p<0.05), though 5µM PD98059 abolished this effect after 24 h (Fig 3A and 3B) .
Role of Sp1 in pitavastatin-enhanced PON1 promoter activation
We examined the relationship of Sp1 to PON1 promoter activity in Huh7
cells. An overexpression of Sp1 significantly increased the PON1 promoter activity in Huh7 cells (relative promoter activity; 17.8 ± 0.5 (control 1.0 ± 0.4, p<0.0001)). However, 50 nM mithramycin, an Sp1 inhibitor, almost attenuated pitavastatin-enhanced PON1 promoter activity.
Role of SREBP-2 phosphorylation in pitavastatin-enhanced PON1 promoter activation
Next we studied the relationship between SREPB-2 phosphorylation and pitavastatin-enhanced PON1 promoter activation in Huh7 cells. The construct with PON1 promoter was transfected, and the mutated SREBP-2 expression plasmid (pCL-SREBP-2 S432/455A) or an empty vector was simultaneously cotransfected. Pitavastatin-enhanced PON1 promoter activity was attenuated by cotransfection with PCL-SREBP-2 S432/455A (Fig 4) .
Role of p44/42 MAP kinase signaling cascade in Sp1 binding to PON1 DNA in Huh7 cells
Finally, we investigated whether pitavastatin-induced phosphorylation of p44/42 MAP kinase was associated with the binding of Sp1 to DNA fragments of the PON1 gene promoter (-187/-159), since pitavastatin enhanced PON1
promoter activation through Sp1. An EMSA showed Sp1-DNA complex bands, which were attenuated following an addition of the competitors and supershifted with the addition of the anti-Sp1 antibodies (Fig 5A) . Treatment with 50 µM pitavastatin increased the band intensity of Sp1-DNA complex (p <0.01).
Pretreatment with 10 µM PD98059 abolished the pitavastatin-increased band intensity (Fig. 5B) .
DISCUSSION
In the present study, pitavastatin affected PON1 gene promoter activity and previous report [15] . On the other hand, pCL-SREBP-2 S432/455A inhibited pitavastatin-enhanced PON1 promoter activity in Huh7 cells (Fig 4) . The result supposed pitavastatin influenced PON1 promoter activity through SREBP-2 which is phosphorylated by p44/42 MAP kinase. The phosphorylations at S432/455A of SREBP-2 were already reported to have no influence on DNA interaction, but they increased its transactivity [18] . Therefore we suggested that pitavastatin-phosphorylated SREBP-2 through p44/42 MAP kinase might influence other transcription factors or cofactors that are important for the function of SREBP-2, for example Sp1, which follows by pitavastatin-increased PON1 promoter activity.
Sp1 is a ubiquitous transcription factor and also reportedly activate PON1 gene transcriptions [23, 27] . We also showed that PON1 gene promoter transcription was associated with Sp1 in this study. Moreover, EMSA results
showed that the binding intensity of Sp1 to DNA fragments of PON1 promoter was increased by treatment with pitavastatin and that PD98059 attenuated pitavastatin-increased band intensity of the Sp1-DNA complex (Fig 5) . These results suggest that pitavastatin activates PON1 transcription through phosphorylation of p44/42 MAP kinase, which increases Sp1-DNA binding.
In conclusion, pitavastatin may phosphorylate SREBP-2 and/or increase the binding of Sp1 to the PON1 gene promoter region through the phosphorylation of p44/42 MAP kinase, and pitavastatin increases PON1 gene transactivation and PON1 protein expression through those mechanisms.
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